Roche and Genentech Company Presentation Alex Szidon, Head of Business Development Genentech Research & Early Development, Pharma Partnering June 2020
The Roche Group: an What we are looking Why we make a innovation-led company for from you good partner 2
The Roche Group A leading healthcare company dedicated to innovation in a sustainable way 1896 Genentech 1 , first 61.5 bn publicly-owned Founded in Basel Family still holds Sales 2019 (CHF) Biotech majority stake ♯ 1 97’735 63,000,000 people treated R&D investor in Employees worldwide worldwide with our healthcare medicines in 2019 Lasting… … and Sustainable 31 >30 medicines Among top companies in Dow Jones FDA Breakthrough on World Health Sustainability Index (Life Sciences Sector) Designations Organization List of for 10 consecutive years Essential Medicines 3 1 Genentech became a full member of the Roche group in March 2009
The leader in personalized healthcare Optimally positioning us for the future Combining pharmaceuticals and diagnostics under one roof together with deep know-how in molecular biology and data science, make Roche a unique partner to drive next step in the evolution of healthcare. Leader in Diagnostics Leader in Pharma 4 Diagnosis Decision Support Therapy Therapy monitoring
The Roche Group: an What we are looking Why we make a innovation-led company for from you good partner 5
Active partnerships across the globe Over 220 partnerships across North America, Europe and Asia Pacific Europe 26% 59% 15% Asia Pacific North America 6
Our approach to Partnering in the Pharma industry We value external innovation and bring our best experts to the table 7
Because a great idea is a great idea… …no matter where it comes from ∼ 50% ∼ 40% of R&D pipeline of total Pharma sales involve a partnership generated from partnered or in-licensed products 8
Roche launched 16 new molecules since 2011 11 out of the 16 are partnered medicines 2011 2012 2013 2014 2015 2016 2017 2018 2019 Partnered medicines 9
We believe in flexibility of deal structures Tailored for mutual value and partners’ wants and needs Option Deal Licensing Buyer Seller Co-development Earn-out M&A 10
Why we make a The Roche Group: an What we are looking innovation-led company good partner for from you 11
What we are looking for in a partnering opportunity Innovative science with the potential to make a significant difference for patients What we are focusing on What we don’t do What we are looking for Clear connection between High disease burden Generics, biosimilars MoA and pathobiology Robust data linking Novel targets OTCs MoA, PK and PD Potential for first- or best-in Animal Health Biomarker strategy class molecules Novel enabling modalities 12
Our focus areas Seeking great science across multiple therapeutic areas Digital & Personalized Oncology & Cancer Immunology & Neuroscience, Research Technologies Immunotherapy Infectious Diseases Ophthalmology & Healthcare Rare Diseases Neurodegeneration Oncogenic drivers GI, Respiratory, Technologies & modalities Robust data sets Rheumatology enabling challenging Neuroinflammation Synthetic lethality Advanced Analytics (AI targets • Innate, Adaptive, incl. Machine learning Neurodevelopmental Fibrosis, Tolerance and Adaptive and Innate Targeted delivery / and deep learning Tissue Regeneration immunity intracellular delivery models) Pain (non-opioid treatments Targets for chronic pain) Neoantigens AI for drug discovery Digital and mobile Hep B & Respiratory technologies Retinal diseases and dry eye Stromal biology Viruses Genomic medicine disease approaches Cell therapies MDR Gram (-) Infections Monogenetic rare diseases Ocular delivery 13
Roche Pharma Partnering IMMUNOLOGY, RESEARCH ALLIANCE & NEUROSCIENCE, INFECTIOUS DISEASE TECHNOLOGIES ASSET MANAGEMENT OPHTHALMOLOGY & SPECIALTY CARE & RARE DISEASES Barbara Lueckel Urs Schleuniger Pat Schleck Phone: +41 79 264 3944 Phone: +41 61 687 7842 Tom Zioncheck Phone: +1 973 420 4497 Email: barbara.lueckel@roche.com Email: urs.schleuniger@roche.com Phone: +41 61 682 17 78 Email: schleckp@gene.com Email: tom.zioncheck@roche.com Mark Schiebler Karl Yen Phone: +41 79 361 1421 R&D OUT-PARTNERING J.C. Lopez Phone: +41 79 573 61 24 Email: mark.schiebler@roche.com Phone: +1 650 467 1877 Email: karl.yen@roche.com Joerg Kazenwadel Email: lopez.julio@gene.com Phone: + 41 61 687 0524 Email: joerg.kazenwadel@roche.com DIGITAL & ASIA ONCOLOGY PERSONALIZED Japan and Korea & CANCER HEALTHCARE COMMUNICATIONS IMMUNOTHERAPY Kaoru Suzuki Gregg Talbert Phone: +81 3 6743 4237 Tiffany Payette Don O’Sullivan Phone: +1 650 225 6405 Email: kaoru.suzuki@roche.com Phone: +41 79 644 41 60 Phone: +1 650 225 4405 Email: talbert.gregg@gene.com Email: tiffany.payette@roche.com Email: osullivan.don@gene.com China, Taiwan & Singapore Erika Pollex Danielle Bittencourt Phone: +1 650 303-4960 Yingjie Wu Phone: +1 650 467 8411 Email: pollexe@gene.com Phone: +86 21 2894 6153 Email: bittencourt.danielle@gene.com Email: yingjie.wu@roche.com 14
Doing now what patients need next 15
Recommend
More recommend
